Moffitt Study Shows Adaptive Therapy Improves Outcomes, Reduces Care Costs for Prostate Cancer Patients

Researchers in Center of Excellence for Evolutionary Therapy at Moffitt Cancer Center are thinking outside the box and studying an alternative approach called adaptive therapy that is based on evolutionary principles and mathematical modeling. In a new article in eLife, the researchers report updated results from a pilot clinical trial evaluating an adaptive therapy approach using the drug abiraterone to treat patients with metastatic castrate-resistant prostate cancer.

Moffitt Researchers Develop Mathematical Model to Predict Patient Outcomes to Adaptive Prostate Cancer Therapy

In an article published in Nature Communications, Moffitt Cancer Center researchers provide a closer look at a mathematical model and data showing that individual patient alterations in the prostate-specific antigen (PSA) biomarker early in cancer treatment can predict outcomes to later treatment cycles of adaptive therapy.